78 (PB068) - Vepafestinib is effective in preclinical models of sarcomas with RET fusion including a brain metastasis model

Abstract

Background: RET fusions are found in an increasing number of undifferentiated pediatric sarcomas, with many tumors occurring in the infantile fibrosarcoma spectrum. Vepafestinib (TAS0953/HM06) is a brain-penetrant 2nd generation RET-selective inhibitor that is also effective against RET solvent front (G810) and gatekeeper (V804) mutations. We evaluated the brain penetrability and efficacy of vepafestinib in preclinical sarcomas models with RET fusion.